Anti-inflammatory Markers in Endometrioma

Muğla Sıtkı Koçman University

Status: Completed

Conditions: Inflammation; Endometrioma

Treatments: Diagnostic Test: Adropin (ng/L)

Study type: Observational

Funder types: Other

Identifiers

NCT04371133

22/08/2019-05

Details and patient eligibility

About

Investigators aimed to measure the serum levels of adropin, salusin-α, netrin-1, and nesfatin-1, anti-inflammatory effects of which have been demonstrated previously, in endometriosis patients and to find out any association of them with insulin resistance.

Full description

Endometriosis is defined as the presence of endometrial gland and stroma outside the endometrial cavity affecting almost 10% of the women of reproductive age. Although benign, it disrupts the quality of life of the inflicted patients through symptoms such as dysmenorrhae, dyspareunia, chronic pelvic pain, and infertility. The pathogenesis of endometriosis has not yet been clearly elucidated, however, recent papers implies an underpinning role of inflammation There is a limited number of studies about the levels of these parameters in endometriosis and to date, no report is available on the levels of adropin and netrin-1 in endometriosis. Likewise, according to the investigator's literature search, no research explaining the association of endometriosis with insulin resistance has yet been published. In present study, in an attempt to describe inflammatory pathways playing a role in endometriosis pathogenesis, Investigators aimed to measure the levels of serum adropin, salusin-α, netrin-1, and nesfatin-1, anti-inflammatory effects of which have been priorly demonstrated, and to find out any association of them with insulin resistance.

Enrollment: 48 patients

Sex: Female

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

·Histopathologically confirmed diagnosis of endometrioma

Exclusion criteria

• Any patients with DM,
• chronic kidney disease (CKD),
• CAD,
• heart failure (HF),
• cerebrovascular accident (CVA),
• malignancy,
• rheumatoid disorder,
• liver disease, and
• active infections were excluded from the study.

Trial design

48 participants in 2 patient groups

Endometrioma

Description:

Endometrioma (n=23)

Treatment:

Diagnostic Test: Adropin (ng/L)

Healthy controls

Description:

Healthy controls Healthy volunteers n=25

Treatment:

Diagnostic Test: Adropin (ng/L)